Losartan/Hydrochlorothiazide
Brand names: Hyzaar, Losartan-Hydrochlorothiazide
At a glance
- Medicare prescriptions, 2024
- 4,917,569
- Medicare drug cost
- $69.7M
- Average cost per prescription
- $14.17
- Clinicians who prescribed it
- 128,945
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Losartan Potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
From the FDA-approved prescribing information (label dated August 2026). Full labels on DailyMed (opens in a new tab)
Boxed warning
WARNING: FETAL TOXICITY When pregnancy is detected, discontinue losartan Potassium tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue losartan potassium tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
The FDA’s strongest warning on a label. It doesn’t mean the drug is unsafe for most people; talk to your doctor or pharmacist before stopping or changing any medicine.
Who prescribes it
- Family Medicine 36.7%
- Internal Medicine 30.3%
- Nurse Practitioners 13.6%
- Cardiology 5.8%
- Physician Assistants 5.0%
- General Practice 2.8%
- Interventional Cardiology 1.9%
- Geriatric Medicine 0.8%
- Nephrology (Kidney) 0.6%
- Endocrinology & Diabetes 0.5%
- Hospitalist 0.2%
- Pulmonology 0.2%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions fell 10% from 2019 to 2024.
Biggest change by state since 2019
- District of Columbia +15%
- Washington +14%
- Utah +13%
- Minnesota +8%
- Colorado +8%
- Puerto Rico (smallest change) −43%
- Iowa (smallest change) −25%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 1 maker on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Redpharm Drug
| Strength | Looks like | Imprint |
|---|---|---|
| 50 mg | white oval tablet, 10 mm, scored to split in 2 | I 6 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
5 recalls since 2020
- Jun 2023 · Strides Pharma Inc. · Class II
Presence of Foreign Substance: Presence of a small piece of blue plastic embedded in the tablet. - Jun 2022 · Pd-Rx Pharmaceuticals, Inc. · Class II
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits - May 2022 · Strides Pharma Inc. · Class II
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits - Apr 2022 · Macleods Pharma Usa Inc · Class II
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits - Mar 2022 · Lupin Pharmaceuticals Inc. · Class II
CGMP Deviations- AZIDO Impurity levels observed to be above acceptable limits
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.